Sunday, July 22, 2018

Domino's Pizza Extends Its Growth Streak

Domino's�Pizza (NYSE:DPZ) announced second-quarter earnings results this week that extended the pizza chain's impressive streak of growth in both its U.S. and international markets.

Here's a look at how the pizza delivery leader's headline results stacked up against the prior-year period:�

�Metric

Q2 2018

Q2 2017

Year-Over-Year Change

Revenue

$779 million

$629 million

24%

Net income

$77 million

$66 million

18%

EPS

$1.78

$1.32

35%

Data source: Domino's financial filings.

What happened this quarter?

Revenue rose 24% thanks to the combination of a quickly growing store base and robust sales gains at existing locations. Domino's profitability took a small step lower, though, as rising expenses outpaced savings from tax cuts to push margins down.

Friends sharing a delivered pizza.

Image source: Getty Images.

Here are some of the key highlights from the quarter:

Comparable-store sales growth was a robust 7% in the core U.S. segment. That marked a slight slowdown from the prior quarter's 8% rate but easily kept Domino's among the best-performing fast-food companies around. The international segment slowed a bit, too, falling to a 4% increase from 5%. Yet this division stayed within management's target of between 3% and 6% for the year. Domino's added 156 stores to its global base, split between 43 locations in the U.S. and 113 new restaurants in outside markets. Operating costs expanded faster than sales, which pushed operating margin down to 16.2% of sales from 18% a year ago. Tax payments dove, but the reduced operating margin combined with higher interest payments to push bottom-line profitability down to 9.9% of sales from 10.5% of sales. The chain spent $219 million repurchasing its stock, which led per-share earnings to rise by 35% compared to the 18% growth in net income. Domino's ended the quarter with $158 million of cash and $3.5 billion in debt. What management had to say

CEO Ritch Allison, in his first quarter as the company's new leader, highlighted the chain's strong sales and store growth metrics." Global retail sales remain strong as we see our franchisees building new stores, growing same store sales and bringing customers back again and again," Allison said.

Management noted that customers reacted positively to tech initiatives like its recent "hotspots" program, which has created over 200,000 non-traditional delivery locations for places like beaches and parks that lack standard addresses. "I'm delighted to report that our franchisees and team members continued to deliver great results across the global Domino's system," Allison concluded.

Looking forward

Domino's doesn't issue specific sales guidance, but its recent results keep the company right on track to meet -- or exceed -- its long-term objectives. In fact, comps in the core U.S. market have been running ahead of management's annual target for the last six months, which suggests the chain has a good shot at improving on last year's 13% overall sales increase in 2018.

Profits are being pinched by increasing wages and higher commodity costs, particularly cheese. Domino's significant debt load, meanwhile, has kept interest payments at a hefty 4% of sales. Still, the chain has generated $166 million of net income through the first half of 2018, or 10.6% of sales, compared to $128 million, or 10.2% of sales in the prior-year period. As long as Domino's continues winning market share at home while expanding its store base internationally, shareholders can expect that profitability uptick to power robust earnings growth.

Saturday, July 21, 2018

Top Stocks To Own Right Now

tags:MIK,CSTR,XIV, &l;p&g;&l;img class=&q;dam-image shutterstock size-large wp-image-1050802082&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1050802082/960x0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Shutterstock

The retirement stories I most hate to hear are about people who entered retirement financially secure but saw that security disappear over the years.

These stories are all too common, and so are the causes of most retirement failures. Usually, investment market declines are not the cause. Ensure your retirement is successful by being aware of the most frequent causes of adverse retirement turnarounds and planning to avoid them. These are the five most common reasons I&a;rsquo;ve identified that cause retirement plans to go off track.

&l;strong&g;Helping too much. &l;/strong&g;Too often, people dip into their retirement funds to give too much money to loved ones. Unfortunately, that often turns out to be money they need later in retirement. This also is known as &a;ldquo;becoming the Bank of Mom &a;amp; Dad.&a;rdquo;

Top Stocks To Own Right Now: The Michaels Companies, Inc.(MIK)

Advisors' Opinion:
  • [By Demitrios Kalogeropoulos]

    The week ahead will likely bring more volatility, particularly for shareholders of�Dave & Buster's�(NASDAQ:PLAY), H&R Block�(NYSE:HRB), and Michaels�(NASDAQ:MIK)�as each of these companies is set to announce quarterly earnings results over the next few days. Let's look at a few key trends to watch for in the reports.

  • [By Ethan Ryder]

    Michaels Companies (NASDAQ:MIK) issued an update on its FY19 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $2.19-2.32 for the period, compared to the Thomson Reuters consensus estimate of $2.32. The company issued revenue guidance of $5.217-5.293 billion, compared to the consensus revenue estimate of $5.26 billion.Michaels Companies also updated its Q2 guidance to $0.12-0.14 EPS.

  • [By Anders Bylund]

    Arts and crafts retailer The Michaels Companies (NASDAQ:MIK) reported first-quarter results in the early-morning hours of Thursday. The company met Wall Street's targets and confirmed that its full-year guidance targets are on track, but the stock still crashed due to an unimpressive slate of second-quarter guidance goals.

  • [By Chris Lange]

    The Michaels Companies, Inc. (NASDAQ: MIK), the arts and crafts retail chain, released its fiscal first-quarter financial results before the markets opened on Thursday. The Irving, Texas-based company said it had $0.39 in earnings per share (EPS) and $1.16 billion in revenue, compared with consensus estimates from Thomson Reuters that called for $0.38 in EPS and $1.15 billion in revenue. The same period from last year had $0.38 in EPS and $1.16 billion in revenue.

  • [By Chris Hill]

    Also, the two look at the sharp sell-offs that the market treated Michaels�(NASDAQ:MIK) and Tailored Brands�(NYSE:TLRD) to yesterday -- what went wrong, and can the companies improve from here? Finally, they dip into the Fool mailbag to explain how a company's market cap compares to the size of its total potential market.

Top Stocks To Own Right Now: Coinstar Inc.(CSTR)

Advisors' Opinion:
  • [By Joseph Griffin]

    Shares of Capstar Financial Holdings Inc (NASDAQ:CSTR) have been assigned an average rating of “Hold” from the five research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $19.75.

  • [By Stephan Byrd]

    Capstar Financial (NASDAQ: CSTR) and Mercantile Bank (NASDAQ:MBWM) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Top Stocks To Own Right Now: region(XIV)

Advisors' Opinion:
  • [By Money Morning News Team]

    This led some traders to purchase leveraged ETFs that move inverse to the VIX, like the�VelocityShares Daily Inv VIX Short Term�(Nasdaq: XIV).

    The VIX is a derivative of the broad S&P 500, and the XIV is a derivative of that derivative.

Friday, July 20, 2018

Best Growth Stocks To Buy Right Now

tags:BWLD,JWN,MED,TBI,ISRG,

Cypress Semiconductor's (NASDAQ:CY) business looked precarious the last couple of years. As part of a strategy to enter the lucrative Internet of Things (IoT) industry, profits were sacrificed in order to generate sales growth and a bigger payoff down the road. After several years of running in the red, it looks like 2018 could be the year Cypress begins to reap the rewards of its gamble.

What a difference a year makes

The first quarter of 2018 was quite different from a year ago. Cypress Semiconductor showed a return to bottom-line profits in the first quarter.

Metric

Q1 2018

Q1 2017

Change (YOY)

Revenue

$582.2 million

$531.9 million

9.5%

Gross profit margin

36.5%

29.5%

N/A

Operating profit (loss) margin

6.1%

(2.6%)

Best Growth Stocks To Buy Right Now: Buffalo Wild Wings Inc.(BWLD)

Advisors' Opinion:
  • [By Steve Symington]

    That's not to say it was a quiet day for every stock on the market. With earnings season ramping up, brewing giant Anheuser-Busch InBev (NYSE:BUD) and restaurant chain Buffalo Wild Wings (NASDAQ:BWLD) served as an exercise in contrast as investors reacted to their respective quarterly reports.

  • [By Peter Graham]

    A long term performance chart shows Dave & Busters Entertainment�tripling in value�before falling back while�small cap upscale gentlemen's clubs and restaurant owner�RCI Hospitality Holdings, Inc (NASDAQ: RICK) began taking off in 2016 and small cap�Buffalo Wild Wings (NASDAQ: BWLD) is being acquired by Arby��s Restaurant Group:

Best Growth Stocks To Buy Right Now: Nordstrom Inc.(JWN)

Advisors' Opinion:
  • [By ]

    Some reasons for my bearishness on retail stocks:

    Higher Energy Prices. Oil prices have rallied dramatically and back to 2014 levels, rising from about $35 a barrel in early 2016 to around $67 Thursday. That's bad news for U.S. retailers, as rising oil prices historically squeeze consumer disposable incomes. That's one reason why I've been consistently raising my short exposure to retail and plan to continue doing so. Shaky Same-Store Sales Growth. Recent improvements to same-store sales at Abercrombie & Fitch (ANF) , Urban Outfitters (URBN) , Dillard's (DDS) , Gap Inc. (GPS) and Macy's (M) come against downgraded expectations, and might not be sustainable anyway. No Deal for Nordstrom (JWN) . The Nordstrom family has apparently abandoned plans to take its namesake company private. I had expressed concerns that this would happen. Higher Interest Rates. A rise in the London Inter-Bank Offered Rate (LIBOR) has recently accelerated. That's bad news for retailers, as many variable-rate consumer debts (particularly mortgages) key off of the LIBOR. This will likely put a damper on mortgage refinancings -- something that many see as an important ingredient for personal-consumption expenditures.

  • [By Motley Fool Staff]

    Nordstrom, Inc. (NYSE:JWN)Q1 2018 Earnings Conference CallMay 17, 2017, 4:45 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Jeremy Bowman]

    A lot has changed since then, however. J.C. Penney badly underperformed its own comparable sales target in the second half of 2016, as comparable sales fell instead of hitting the 3-4% mark the company had projected. Its peers continued to struggle -- Macy's�(NYSE:M),�Kohl's�(NYSE:KSS), and�Nordstrom�(NYSE:JWN) all reported declining comps in the fourth quarter, and Macy's said last year it would close 100 stores.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Nordstrom, Inc. (NYSE: JWN) which traded down about 2% at $51.92. The stock��s 52-week range is $37.79 to $54.00. Volume was 2.3 million compared to the daily average volume of 2.0 million.

  • [By Steve Symington]

    But several individual companies bucked the indexes' trend. Read on to learn why MiMedx Group (NASDAQ:MDXG), Core Laboratories (NYSE:CLB), and Nordstrom (NYSE:JWN) trailed the broader market today.

  • [By Paul Ausick]

    One bit of good news for Walmart is that its Sam’s Club warehouse stores scored an 80 to tie for third behind Costco Wholesale Corp. (NASDAQ: COST) at 83 and Nordstrom Inc. (NYSE: JWN) at 81.

Best Growth Stocks To Buy Right Now: MEDIFAST INC(MED)

Advisors' Opinion:
  • [By Lisa Levin] Gainers Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares rose 35.8 percent to $3.00. Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares surged 32 percent to $8.94 after reporting upbeat Q1 earnings. Carbon Black, Inc. (NASDAQ: CBLK) gained 29.6 percent to $24.62. Carbon Black priced its IPO at $19 per share. California Resources Corporation (NYSE: CRC) shares rose 26.8 percent to $32.70 following upbeat Q1 earnings. Pandora Media, Inc. (NYSE: P) gained 25 percent to $7.185 after reporting strong quarterly results. Medifast, Inc. (NYSE: MED) shares climbed 23.7 percent to $122.87 after the company reported strong Q1 results and raised its FY18 guidance. Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.2 percent to $8.4999 after reporting Q2 results. Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) gained 22.2 percent to $41.27 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban. Shake Shack Inc (NYSE: SHAK) rose 22.2 percent to $57.955 after the company reported upbeat results for its first quarter and raised its FY18 guidance. Atomera Incorporated (NASDAQ: ATOM) jumped 19.7 percent to $6.12 after reporting Q1 results. Super Micro Computer, Inc. (NASDAQ: SMCI) rose 16.4 percent to $21.00 after reporting strong preliminary results for the third quarter. Titan International, Inc. (NYSE: TWI) shares rose 16.4 percent to $12.21 following Q1 earnings. Integer Holdings Corporation (NYSE: ITGR) shares gained 14.9 percent to $63.75 following Q1 results. Control4 Corporation (NASDAQ: CTRL) shares climbed 14.5 percent to $23.98 folloiwng strong Q1 results. B&G Foods, Inc. (NYSE: BGS) climbed 12.6 percent to $25.40 after reporting Q1 earnings. HMS Holdings Corp (NASDAQ: HMSY) shares gained 10 percent to $19.59 after reporting upbeat quarterly earnings. Viavi Solutions Inc. (NASDAQ: VIAV) rose 7 percent to $10.09 following Q3 r
  • [By Lisa Levin]

    Medifast, Inc. (NYSE: MED) shares were also up, gaining 20 percent to $119 after the company reported strong Q1 results and raised its FY18 guidance.

  • [By Ethan Ryder]

    MediBloc (CURRENCY:MED) traded 3.9% lower against the U.S. dollar during the 1-day period ending at 20:00 PM E.T. on June 13th. One MediBloc token can now be purchased for $0.0083 or 0.00000131 BTC on major cryptocurrency exchanges including Coinrail, Gate.io and Bibox. During the last seven days, MediBloc has traded 36.5% lower against the U.S. dollar. MediBloc has a total market cap of $24.58 million and $216,935.00 worth of MediBloc was traded on exchanges in the last day.

  • [By Lisa Levin]

    Medifast, Inc. (NYSE: MED) shares were also up, gaining 25 percent to $124.60 after the company reported strong Q1 results and raised its FY18 guidance.

Best Growth Stocks To Buy Right Now: TrueBlue Inc.(TBI)

Advisors' Opinion:
  • [By Stephan Byrd]

    American Century Companies Inc. grew its holdings in shares of Trueblue Inc (NYSE:TBI) by 24.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 95,307 shares of the business services provider’s stock after purchasing an additional 18,680 shares during the period. American Century Companies Inc. owned approximately 0.23% of Trueblue worth $2,468,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    Russell Investments Group Ltd. grew its stake in Trueblue Inc (NYSE:TBI) by 21.2% during the first quarter, HoldingsChannel reports. The fund owned 137,178 shares of the business services provider’s stock after purchasing an additional 23,951 shares during the quarter. Russell Investments Group Ltd.’s holdings in Trueblue were worth $3,553,000 at the end of the most recent quarter.

  • [By Logan Wallace]

    Media stories about Trueblue (NYSE:TBI) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trueblue earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the business services provider an impact score of 45.3296498009881 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

  • [By Joseph Griffin]

    Trueblue Inc (NYSE:TBI) has received a consensus rating of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $27.50.

  • [By Logan Wallace]

    Trueblue (NYSE: TBI) is one of 23 public companies in the “Help supply services” industry, but how does it contrast to its rivals? We will compare Trueblue to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.

Best Growth Stocks To Buy Right Now: Intuitive Surgical Inc.(ISRG)

Advisors' Opinion:
  • [By Brian Feroldi]

    TransEnterix (NYSEMKT:TRXC) recently surprised investors on the upside when it reported its first-quarter results. The company's�Senhance�surgical system is off to a fast start right out of the gate, and it has attracted a lot of positive attention from the medical community. This just goes to show how much demand is out there for an�alternative to Intuitive Surgical's (NASDAQ: ISRG)�dominant da Vinci platform.�

  • [By Stephan Byrd]

    MSA Safety (NYSE: MSA) and Intuitive Surgical (NASDAQ:ISRG) are both industrial products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

  • [By Brian Stoffel]

    That's the basic business model behind the two companies in today's match-up: surgical robot maker�Intuitive Surgical�(NASDAQ:ISRG) and medical device maker�Medtronic�(NYSE:MDT). If you're interested in investing in this field, the question becomes: Which is the better stock to buy at today's prices?

Thursday, July 19, 2018

Mindtree Q1 PAT may dip 11.8% QoQ to Rs. 150 cr: HDFC Securities


HDFC Securities has come out with its first quarter (April-June�� 18) earnings estimates for the Technology sector. The brokerage house expects Mindtree to report net profit at Rs. 150 crore down 11.8% quarter-on-quarter (up 60.7% year-on-year).


Net Sales are expected to increase by 7.4 percent Q-o-Q (up 21.9 percent Y-o-Y) to Rs. 1,572 crore, according to HDFC Securities.


Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 1.8 percent Q-o-Q (up 61.2 percent Y-o-Y) to Rs. 231 crore.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on Jul 18, 2018 12:30 pm

Monday, July 16, 2018

Somewhat Favorable News Coverage Somewhat Unlikely to Impact Colony Bankcorp (CBAN) Stock Price

Media headlines about Colony Bankcorp (NASDAQ:CBAN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Colony Bankcorp earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the financial services provider an impact score of 46.5935973221915 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Colony Bankcorp stock remained flat at $$17.55 during midday trading on Thursday. 88 shares of the company’s stock traded hands, compared to its average volume of 3,222. The stock has a market cap of $150.22 million, a P/E ratio of 14.24 and a beta of 0.35. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.77 and a quick ratio of 0.77. Colony Bankcorp has a 52 week low of $11.10 and a 52 week high of $19.50.

Get Colony Bankcorp alerts:

Colony Bankcorp (NASDAQ:CBAN) last announced its earnings results on Wednesday, April 18th. The financial services provider reported $0.37 earnings per share for the quarter. The business had revenue of $12.56 million during the quarter. Colony Bankcorp had a net margin of 15.65% and a return on equity of 12.04%.

The company also recently announced a quarterly dividend, which was paid on Friday, June 29th. Stockholders of record on Monday, June 4th were paid a $0.05 dividend. The ex-dividend date was Friday, June 1st. This represents a $0.20 annualized dividend and a dividend yield of 1.14%.

In other news, insider M. Edward Jr. Hoyle bought 2,625 shares of the firm’s stock in a transaction dated Wednesday, May 30th. The stock was acquired at an average cost of $16.08 per share, for a total transaction of $42,210.00. Following the completion of the purchase, the insider now owns 6,121 shares of the company’s stock, valued at $98,425.68. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders bought 3,743 shares of company stock valued at $60,162 over the last 90 days. Insiders own 5.45% of the company’s stock.

About Colony Bankcorp

Colony Bankcorp, Inc operates as the holding company for Colony Bank that provides banking products and services to commercial and consumer customers. It offers various deposit products, including demand, savings, and time deposits. The company also offers loans to small and medium-sized businesses; residential and commercial construction, and land development loans; commercial real estate loans; commercial loans; agri-business and production loans; residential mortgage loans; home equity loans; and consumer loans.

Insider Buying and Selling by Quarter for Colony Bankcorp (NASDAQ:CBAN)

Friday, July 13, 2018

Esperion Therapeutics (ESPR) Earns Daily Media Sentiment Rating of 0.06

Media stories about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.5459109210657 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

Get Esperion Therapeutics alerts: Esperion Therapeutics (ESPR) Downgraded by Northland Securities (americanbankingnews.com) Esperion Therapeutics Inc (ESPR) Expected to Announce Earnings of -$1.77 Per Share (americanbankingnews.com) Options Traders Expect Huge Moves in Esperion Therapeutics (ESPR) Stock (zacks.com) CLASS ACTION UPDATE for ESPR, SYMC, and PPG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (finance.yahoo.com) DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (finance.yahoo.com)

Shares of Esperion Therapeutics traded up $0.26, reaching $41.49, during trading on Thursday, MarketBeat Ratings reports. The company had a trading volume of 13,680 shares, compared to its average volume of 879,731. Esperion Therapeutics has a one year low of $33.06 and a one year high of $82.68. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.94 and a beta of 2.37.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.56) by ($0.17). During the same quarter last year, the company earned ($1.80) earnings per share. sell-side analysts predict that Esperion Therapeutics will post -6.31 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on ESPR. Northland Securities raised their price target on Esperion Therapeutics from $100.00 to $121.00 and gave the stock a “buy” rating in a research note on Thursday, April 19th. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. Chardan Capital raised their price target on Esperion Therapeutics from $75.00 to $100.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 27th. ValuEngine raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Bank of America reissued an “underperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, May 2nd. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $89.08.

In other Esperion Therapeutics news, major shareholder Target N. V. Biotech bought 50,000 shares of the stock in a transaction on Friday, June 29th. The shares were purchased at an average price of $39.48 per share, with a total value of $1,974,000.00. Following the acquisition, the insider now directly owns 3,182,964 shares of the company’s stock, valued at approximately $125,663,418.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Target N. V. Biotech bought 60,000 shares of the stock in a transaction on Thursday, June 21st. The stock was acquired at an average cost of $38.57 per share, for a total transaction of $2,314,200.00. Following the acquisition, the insider now directly owns 3,132,964 shares in the company, valued at $120,838,421.48. The disclosure for this purchase can be found here. Insiders acquired a total of 410,000 shares of company stock worth $16,190,100 in the last ninety days. Insiders own 32.50% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Tuesday, July 10, 2018

Navios Maritime Acquisition (NNA) Trading Up 9.1%

Navios Maritime Acquisition Co. (NYSE:NNA)’s share price traded up 9.1% during trading on Monday . The stock traded as high as $0.62 and last traded at $0.60. 733,073 shares changed hands during trading, an increase of 17% from the average session volume of 627,412 shares. The stock had previously closed at $0.55.

Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Navios Maritime Acquisition from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 28th. ValuEngine raised shares of Navios Maritime Acquisition from a “sell” rating to a “hold” rating in a research report on Wednesday, May 9th. Finally, JPMorgan Chase & Co. downgraded shares of Navios Maritime Acquisition from a “neutral” rating to an “underweight” rating in a research report on Friday, April 20th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Navios Maritime Acquisition currently has an average rating of “Hold” and an average price target of $1.63.

Get Navios Maritime Acquisition alerts:

The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 2.32. The stock has a market capitalization of $83.35 million, a P/E ratio of -5.00 and a beta of 0.89.

Navios Maritime Acquisition (NYSE:NNA) last posted its earnings results on Thursday, May 10th. The shipping company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. The firm had revenue of $40.32 million for the quarter, compared to the consensus estimate of $38.68 million. Navios Maritime Acquisition had a negative net margin of 52.11% and a negative return on equity of 9.11%. equities research analysts anticipate that Navios Maritime Acquisition Co. will post -0.37 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 27th. Shareholders of record on Thursday, June 21st were given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 13.56%. The ex-dividend date of this dividend was Wednesday, June 20th. Navios Maritime Acquisition’s payout ratio is -66.67%.

Institutional investors have recently bought and sold shares of the business. Millennium Management LLC acquired a new position in Navios Maritime Acquisition during the fourth quarter worth $171,000. Deutsche Bank AG grew its position in shares of Navios Maritime Acquisition by 137.3% in the fourth quarter. Deutsche Bank AG now owns 186,773 shares of the shipping company’s stock valued at $205,000 after purchasing an additional 108,077 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Navios Maritime Acquisition by 28.8% in the fourth quarter. California Public Employees Retirement System now owns 369,556 shares of the shipping company’s stock valued at $410,000 after purchasing an additional 82,702 shares during the last quarter. Finally, BlackRock Inc. grew its position in shares of Navios Maritime Acquisition by 2.3% in the fourth quarter. BlackRock Inc. now owns 3,985,852 shares of the shipping company’s stock valued at $4,424,000 after purchasing an additional 90,608 shares during the last quarter. 18.06% of the stock is currently owned by hedge funds and other institutional investors.

About Navios Maritime Acquisition

Navios Maritime Acquisition Corporation provides marine transportation services worldwide. The company owns a fleet of crude oil, refined petroleum product, and chemical tankers. It charters its vessels to oil companies, refiners, and large vessel operators under long, medium, and short term charters.

Monday, July 9, 2018

Best Biotech Stocks To Buy For 2019

tags:AMGN,BIIB,ARQL,ALNY, &l;p&g;&l;img class=&q;dam-image ap size-large wp-image-c6a6e9a6e5e8471fae6d84f5cff3c6ce&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/c6a6e9a6e5e8471fae6d84f5cff3c6ce/960x0.jpg?fit=scale&q; data-height=&q;532&q; data-width=&q;960&q;&g; A house is under construction Friday, May 4, 2018, in Roseville, Calif. Federal data released Friday shows California has surpassed the United Kingdom to become the world fifth largest economy, with real estate and financial services leading other economic sectors in driving the state&s;s economic growth. (AP Photo/Rich Pedroncelli)

Places like Seattle, Austin, Washington, D.C., and Cambridge are endowed with large numbers of highly educated people. Thanks to sectors like software, biotechnology and IT, job growth has recovered from its pre-recession levels and home prices have also surpassed their pre-recession peak. Companies like Twitter and Facebook have had to raise salaries to keep their workers from moving to larger numbers of fast-growing and power-hungry startups. These brain hubs are prime models of economic development gone good and their fortunes have caused rent and home prices to skyrocket &a;ndash; not such good news for those not able to afford them.

Best Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors' Opinion:
  • [By Logan Wallace]

    AlphaMark Advisors LLC cut its position in shares of Amgen (NASDAQ:AMGN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,973 shares of the medical research company’s stock after selling 1,638 shares during the period. Amgen comprises about 2.0% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 7th largest position. AlphaMark Advisors LLC’s holdings in Amgen were worth $4,769,000 at the end of the most recent reporting period.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.72 million shares from the previous level of 9.62 million. Shares were last seen at $184.61 in a 52-week trading range of $161.13 to $201.23.

  • [By Keith Speights]

    The big reason Humira will maintain its position at the top is the U.S. market. U.S. sales of the drug are projected to be around $12.2 billion in 2024. That's not much lower than Humira's 2017 U.S. sales of nearly $12.4 billion. Will Amgen's (NASDAQ:AMGN) biosimilar Amjevita, which will go on sale in the U.S. effective Jan. 31, 2023, really make that small of a dent in Humira's sales? Not really. The impact will be greater than the 2024 projections indicate.

  • [By Trey Thoelcke]

    Amgen Inc. (NASDAQ: AMGN) shares saw a nice bump after the U.S. Food and Drug Administration (FDA) on Thursday approved Aimovig (erenumab), Amgen’s preventive treatment of migraine in adults. It is the first FDA-approved preventive migraine treatment in a new class of drugs, which work by blocking the activity of calcitonin gene-related peptide, which is believed to play a critical role in migraine attacks.

  • [By Joseph Griffin]

    Field & Main Bank grew its stake in shares of Amgen (NASDAQ:AMGN) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,153 shares of the medical research company’s stock after buying an additional 345 shares during the quarter. Field & Main Bank’s holdings in Amgen were worth $708,000 at the end of the most recent quarter.

  • [By Max Byerly]

    Gables Capital Management Inc. purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,023 shares of the medical research company’s stock, valued at approximately $174,000.

Best Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors' Opinion:
  • [By Benzinga News Desk]

    A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link

    ECONOMIC DATA Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week Personal Income Apr. Up 0.3%, Personal Spending Up 0.6% The Chicago PMI for May is schedule for release at 9:45 a.m. ET. The pending home sales index for April will be released at 10:00 a.m. ET. The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET. The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET. Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET. Fed Governor Lael Brainard will speak at 1:00 p.m. ET. Data on money supply for the recent week will be released at 4:30 p.m. ET. Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET. ANALYST RATINGS Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.

  • [By Chris Lange]

    Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.

Best Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors' Opinion:
  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Cory Renauer]

    What's behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc.�(NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we'll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month's Gain �Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85% Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40% Vivis Inc. (Nasdaq: VVUS) $0.77 150.41% Adomani Inc. (Nasdaq: ADOM) $1.49 137.68% NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88% Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06% Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12% ArQule Inc. (Nasdaq: ARQL) $4.88 90.74% LiqTech International Inc. (NYSE: LIQT) $0.66 85.60% Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month's gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Best Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:
  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick -- but with a couple of qualifications. First, I didn't think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

Friday, July 6, 2018

Earnings: 3 Hot Stocks to Watch This Month

So far, it's been a pretty underwhelming year for the overall stock market. The S&P 500, for instance, is up just 2% year to date. But some tech stocks have outperformed the market impressively during this time. Netflix�(NASDAQ:NFLX), Facebook�(NASDAQ:FB), and Alphabet�(NASDAQ:GOOGL) (NASDAQ:GOOG), for instance, have all easily beaten the broader market. Year to date, Netflix, Facebook, and Alphabet are up 104%, 10%, and 7%, respectively.

With performance like this, investors have high expectations for all three companies going into their upcoming earnings reports -- all of which are due this month. Ahead of their quarterly updates, here's a look at some of the key items investors will want to watch.

A group of young people watching TV

Image source: Getty Images.

Netflix

The one metric arguably most important to Netflix's success is its streaming members. Growth in streaming members is what drives Netflix's top line. And it's what supports its aggressive reinvestment into original content production, third-party content acquisition, and marketing. In Netflix's most recent quarter, the company added 7.4 million streaming members sequentially,�crushing management's guidance for 6.4 million net adds during the period.�

Going into Netflix's first quarter, management guided for 6.2 million net new members. Highlighting the company's momentum, this would be the most members Netflix has ever added in its second quarter.

Other notable areas for investors to check on when Netflix's second-quarter results go live include the company's revenue growth, international subscribers, and operating margin.

Facebook

For Facebook investors, it all boils down to growth. The social network has spoiled shareholders with uncanny growth rates for years -- and the first quarter of 2018 was no exception. Revenue increased 49% year over year, and earnings per share (EPS) soared 63% year over year.�On average, analysts expect Facebook's second-quarter revenue and EPS to come in at $13.3 billion and $1.97, respectively. This implies year-over-year growth of 43% and 49%, suggesting analysts expect Facebook's strong momentum to persist.�

Since Facebook has habitually outperformed analyst expectations, the social network may have to deliver results above these consensus estimates in order to live up to investors' expectations.

Investors should also watch Facebook's operating expenses and user growth.

Alphabet

For Alphabet, investors should check in on what management calls its "three big areas." These are its cloud, YouTube, and hardware -- and they're all growing very rapidly.

Of these three businesses, YouTube is almost certainly the biggest. Accounted for in Alphabet's Google properties revenue, YouTube was one of the key drivers for the 26% year-over-year growth in this segment's revenue during Q1, management said.�In addition, YouTube channels with creators earning six figures on the platform increased 40% year over year, highlighting strong growth in the YouTube community.

Cloud and hardware are both accounted for in Alphabet's Google other segment, which saw revenue increase from $3.2 billion in the year-ago quarter to $4.4 billion in the first quarter of 2018, representing 36% growth. Investors should look for these two important businesses to help drive a similar segment growth in Q2.

When Alphabet reports its second-quarter results, investors may also want to take a look at the company's advertising revenue growth, momentum in the Android app store, and overall top- and bottom-line numbers.

Netflix, Facebook, and Alphabet will report their second-quarter results after market close on Jul. 16,�25,�and 23,�respectively.

Thursday, July 5, 2018

Columbia Banking System (COLB) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Columbia Banking System (NASDAQ:COLB) from a sell rating to a hold rating in a research note released on Wednesday.

According to Zacks, “Columbia Banking System, Inc. is a registered bank holding company whose wholly owned subsidiary, Columbia State Bank,conducts a full-service commercial banking business. Headquartered in Tacoma, Washington, the Company provides a full range of banking services to small and medium-sized businesses, professionals and other individuals through banking offices located in the Tacoma metropolitan area and contiguous parts of the Puget Sound region of Washington, as well as the Longview and Woodland communities in southwestern Washington. “

Get Columbia Banking System alerts:

Other research analysts have also recently issued reports about the company. BidaskClub raised Columbia Banking System from a hold rating to a buy rating in a report on Thursday, May 24th. DA Davidson lowered their price target on Columbia Banking System from $51.00 to $49.00 and set a buy rating on the stock in a report on Friday, April 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $48.20.

Shares of Columbia Banking System opened at $41.50 on Wednesday, MarketBeat reports. Columbia Banking System has a 52-week low of $35.67 and a 52-week high of $48.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.82 and a current ratio of 0.83. The stock has a market capitalization of $3.04 billion, a P/E ratio of 18.95, a P/E/G ratio of 1.61 and a beta of 1.14.

Columbia Banking System (NASDAQ:COLB) last posted its quarterly earnings results on Thursday, April 26th. The financial services provider reported $0.59 EPS for the quarter, missing the Zacks’ consensus estimate of $0.66 by ($0.07). Columbia Banking System had a return on equity of 9.04% and a net margin of 24.05%. The business had revenue of $138.62 million during the quarter, compared to analysts’ expectations of $142.70 million. During the same period in the prior year, the firm posted $0.50 earnings per share. equities research analysts forecast that Columbia Banking System will post 2.58 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Brown Advisory Inc. lifted its holdings in Columbia Banking System by 43.6% in the 1st quarter. Brown Advisory Inc. now owns 28,480 shares of the financial services provider’s stock worth $1,195,000 after purchasing an additional 8,644 shares in the last quarter. Principal Financial Group Inc. increased its stake in Columbia Banking System by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 645,287 shares of the financial services provider’s stock worth $27,070,000 after acquiring an additional 16,111 shares during the last quarter. CIBC World Markets Inc. bought a new stake in Columbia Banking System in the 1st quarter worth approximately $424,000. Xact Kapitalforvaltning AB increased its stake in Columbia Banking System by 40.6% in the 1st quarter. Xact Kapitalforvaltning AB now owns 11,088 shares of the financial services provider’s stock worth $465,000 after acquiring an additional 3,200 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Columbia Banking System by 2.2% in the 1st quarter. Legal & General Group Plc now owns 149,798 shares of the financial services provider’s stock worth $6,287,000 after acquiring an additional 3,163 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Columbia Banking System Company Profile

Columbia Banking System, Inc operates as the bank holding company for Columbia State Bank that provides a range of banking services to small and medium-sized businesses, professionals, and individuals in Washington, Oregon, and Idaho. It offers personal banking products and services, including noninterest and interest-bearing checking, saving, money market, and certificate of deposit accounts; home mortgages for purchases and refinances, home equity loans and lines of credit, and personal loans; debit and credit cards; and digital banking services.

Get a free copy of the Zacks research report on Columbia Banking System (COLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Wednesday, July 4, 2018

3 Top Dividend Stocks to Buy Right Now

Finding the best dividend stocks involves selecting companies that have the financial stability to continue paying dividends for years to come, a healthy yield, and a solid business that can weather the inevitable tides of the stock market.

To help you track down a few such companies, we asked a few Motley Fool contributors for some to dividend stocks you should consider adding to your portfolio right now. Here's why Procter & Gamble (NYSE:PG), Microsoft (NASDAQ:MSFT), and Verizon Communications (NYSE:VZ) made it on to their list.

Person sitting in front of paper charts and a tablet.

Image source: Getty Images.

Adjusting to a changing market

Reuben Gregg Brewer (The Procter & Gamble Company): Consumer tastes are changing, and that's having a negative impact on Procter & Gamble, whose stock is down around 15% so far this year. But the consumer products giant hasn't been sitting still; it's adjusting to better serve customers.

The biggest change was the decision to slim down, getting rid of smaller and unprofitable brands. That effort is complete, allowing P&G to focus on its largest and most important businesses, including iconic brands like Gillette, Bounty, and Pampers. Procter & Gamble's core strengths are in research & development, marketing, and distribution, so putting more of its money and time behind a smaller portfolio of brands makes complete sense.

It's also been augmenting its product lineup by introducing "natural" versions of its iconic brands to better align with current consumer demand. In addition, it has been more aggressively taking on internet-based competitors. These are all hard choices that require near-term sacrifices for a long-term benefit. Fiscal 2017 revenues, for example, fell about 0.5%.�

PG Revenue (TTM) ChartImage source: PG Revenue (TTM) data by YCharts.

However, nine months into fiscal 2018, we're starting to see improved results as P&G's top line advanced 3% year over year. So, the combination of its efforts appear to be taking hold. That, however, is being obscured somewhat today by rising costs, notably for transportation. While investors are worrying about the current headwind (which will eventually get resolved by price increases), you can buy P&G with a yield of nearly 4% and pay more attention to the improving big picture.� �

A great software company

Ashraf Eassa (Microsoft): Software giant Microsoft isn't the highest-yielding stock on the market -- its dividend yield is just 1.7% as of writing -- but it's a phenomenal business that should continue to do well over the long term.

Microsoft's growth, despite the fact that it's already a huge business, continues to be impressive. Last quarter, the company reported that its revenue surged 16% to an eye-popping $26.8 billion, with operating income -- my favorite measure of a business's financial health -- growing 23% to $8.3 billion.

The company isn't a one-trick pony, either, with its growth being relatively broad-based. For example, last quarter, Microsoft's Productivity and Business Process segment enjoyed 17% revenue growth, its Intelligent Cloud business unit saw sales grow by 15%, and its More Personal Computing segment saw revenue rise by 11%.

Microsoft has a lot of great product franchises and business units that have delivered and could continue to deliver excellent, highly profitable growth. So, if you're looking for a solid business that, in addition to offering investors a real opportunity for significant share price appreciation, also pays a reasonable dividend, Microsoft is definitely worth a look.

A bet on emerging wireless tech

Chris Neiger (Verizon): Verizon hardly needs an introduction, but it's worth taking a second to consider the company's position in the mobile wireless market. Even with increased competition in the cellular space over the past few years from AT&T and T-Mobile, Verizon still remains the biggest carrier in the U.S. by customers. Not only that, but Verizon is bent on leading the competition in the nascent 5G wireless market as well.

5G will allow for faster uploads and downloads across the mobile internet, enhance wireless connections for Internet of Things devices, and bring new business opportunities for telecoms like fixed wireless broadband. The push for 5G technology is growing across the globe, and in the U.S., Verizon is quickly becoming a leader.

The company launched 5G tests in five markets this year and aims to start commercial 5G services next year. If you think 5G is just another cell-phone company gimmick, consider that this new tech is expected to become a $251 billion market by 2025.

Not only does 5G offer new ways for the company to grow its wireless and home broadband businesses, it's also becoming clear that Verizon is looking to 5G to enhance its content business as well. You may recall that Verizon currently owns Yahoo!, AOL, and other content services, which are housed under its Oath subsidiary. Well, last month, Oath CEO Tim Armstrong�(formerly the CEO of AOL)�told CNBC in an interview: "That's why 5G is important. It's more speed, but it's also amazing amounts of compute power for us to do different types of content."

Investors will have to be patient in waiting for Verizon to launch its�commercial 5G services next year, and understand that it could take a few more years before it spreads across the country. Nevertheless, it's clear that the nation's No. 1 wireless telecom is taking the right steps now to benefit from this new technology in the coming years.

With Verizon's dividend yield at about 4.7% right now and its shares trading at just 6.6 times the company's trailing earnings -- along with its growing 5G potential -- this dividend stock should easily earn a spot on nearly any income investor's short list.�